Knowledge Center

FLIR Systems Receives U.S. Military Contract

Sensor systems developer, FLIR Systems (FLIR), landed a $74.7 million contract with the U.S. military on October 2. They will provide TacFLIR surveillance cameras in support of the U.S. Army EO/IR-Force Protection (FP) program.   Sonal detected the event and sent an alert at 8:00 am. The next trade occurred during the pre-market trading hours […]

Read more...

Novo Nordisk Gets FDA Approval For Fast-Acting Insulin

On September 29, the FDA approved Novo-Nordisk’s (NVO) new drug to treat diabetes. Fiasp is fast-acting insulin that controls post-meal spikes in blood sugar. It works faster than existing drugs on the market and is already approved in both Canada and Europe.   Sonal caught the news and sent an alert at 11:03 am. The […]

Read more...

Zoegenix Climbs on Clinical Trial Results

On September 29, Zogenix (ZGNX) reported positive results from its phase 3 clinical trial for the drug ZX008. The drug treats a rare form of epilepsy known as Dravet Syndrome.   Sonal caught the news at 7:00 am and sent out a level 2 alert. The stock price immediately surged but then faded after the […]

Read more...

FDA Accepts Application for Investigational New Drug From Sangamo and Bioverativ

On October 2, Sangamo Biosciences (SGMO) and Bioverativ Inc. (BIVV) announced that the FDA accepted their application for an investigational new drug (IND). The drug, ST-400, is a gene-edited cell therapy candidate for people with transfusion-dependent-beta-thalassemia. There are about 100,000 patients being treated worldwide for this disease, which requires frequent blood transfusions.   Sonal sent […]

Read more...

Akebia Reports Successful Clinical Trial Results

On September 26, Akebia Therapeutics (AKBA) reported positive results from a phase 2 clinical trial of the drug Vadadustat. The study results came from Japanese patients with anemia associated with non-dialysis chronic kidney disease and confirmed prior findings.   Sonal detected the event and sent out an alert at 7:00 am. The next trade occurred […]

Read more...

Aldeyra Therapeutics Soars on Clinical Trial Results

On September 12, Aldeyra Therapeutics reported positive results from its clinical trial of a treatment for dry eye disease. The company plans to continue its phase 2 clinical trials in early 2018. The news triggered a Sonal level 2 alert at 7:00 am before the stock price rose from $4. The stock price surged over […]

Read more...

Alnylam Pharmaceuticals Reports Clinical Trial Success

On September 20, Alnylam Pharmaceuticals (ALNY) reported exciting stage 3 clinical trial results. Its drug, patisiran, treats a rare nerve disorder called familial amyloid polyneuropathy. Alnylam will seek regulatory approval for patisiran later this year. Sonal sent out a level 2 alert at 7 am, and the next trade was at $93.50. The price rose […]

Read more...

AECOM Reveals Stock Repurchase Program

After the close of the markets on September 21, AECOM (ACM) unveiled a new capital allocation policy and stock repurchase program. AECOM is a global infrastructure firm that plans to spend all available free cash flow to pay down debt until reaching a target level sometime in 2018. This plan includes a stock repurchase program […]

Read more...

QUAD Lands $450 Million Contract

On September 20, Quad Graphics reported that it landed a $450 million printing contract. The Minnesota-based company will print all catalogs for the online retailer and fellow Minnesotans, Bluestem Brands, Inc.   The news triggered a level 3 Sonal alert at 4:05 pm. The next trade occurred at 4:13 pm in after-hours trading for $20.1645. […]

Read more...

LCI Receives FDA Approval for New Drug

Lannett Company (LCI) announced on September 27 that is had received FDA approval for a new drug. The Oxycodone and Acetaminophin tablets USP, 5 mg/325 mg and 10 mg/325 mg are the therapeutic equivalent to the drug Percocet. U.S. sales of Oxycodone and Acetaminophin tablets USP, 5 mg/325 mg and 10 mg/325 mg totaled around […]

Read more...